Study Condition(s): Small Cell Lung Cancer
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
Study Alias: JZHB
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Inclusion Criteria: -Participants must have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage -Participants must have adequate organ function -Participants must have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale -Participants must have discontinued previous treatments for cancer. -Participants must be able to swallow capsules
Exclusion Criteria: -Participants must not be currently enrolled in a clinical study -Participants must not have a serious concomitant systemic disorder -Participants must not have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C -Participants must not have a significant cardiac condition -Participants must not have previously received an aurora kinase inhibitor